prucalopride (Resotran, Motegrity)

From Aaushi
Jump to navigation Jump to search

Indications

Contraindications

Dosage

  • 2 mg PO QD
  • 1 mg P QD > 65 years of age

Adverse effects

Mechanism of action

More general terms

References

  1. 1.0 1.1 Therapeutics Letter #108. Therapeutics Initiative Drugs to Avoid. http://www.ti.ubc.ca/2018/01/04/108-drugs-avoid/
  2. 2.0 2.1 Brooks M FDA OKs Prucalopride (Motegrity) for Chronic Idiopathic Constipation. Medscape - Dec 18, 2018. https://www.medscape.com/viewarticle/906732
  3. 3.0 3.1 Musa A, Geimadi A, Georgis MT et al Ogilvie Syndrome (Acute Colonic Pseudo-obstruction): Early Recognition and Treatment Are Key. Medscape. Nov 18, 2022 https://reference.medscape.com/slideshow/ogilvie-syndrome-6014904

Database